Diabetes mellitus and comorbid depression: Improvement of both diseases with milnacipran. a replication study (results of the Austrian major depression diabetes mellitus study group)

Neuropsychiatric Disease and Treatment

Volumn 8, Issue , 2012, Pages 355-360

  Abrahamian, Heidemarie ^a   Hofmann, Peter ^b   Kinzl, Johann ^c   Toplak, Hermann ^b  

^a OTTO WAGNER HOSPITAL   (Austria)

^b UNIVERSITY HOSPITAL GRAZ   (Austria)

^c UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Depression; Diabetes; Metabolic control; Metformin; Milnacipran

Indexed keywords

CHOLESTEROL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; METFORMIN; MILNACIPRAN; TRIACYLGLYCEROL;

ADULT; AGED; AGITATION; ARTICLE; BECK DEPRESSION INVENTORY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DRUG RESPONSE; DRUG WITHDRAWAL; DYSURIA; FEMALE; GLUCOSE BLOOD LEVEL; HEART PALPITATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; SIDE EFFECT; SWEATING; TRIACYLGLYCEROL BLOOD LEVEL; URINE RETENTION; WEIGHT REDUCTION;

EID: 84866533273     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/ndt.s33679     Document Type: Article

References (26)

1. Katon WJ. The comorbidity of diabetes mellitus and depression. Am J Med. 2008;121(11 Suppl 2):S8-S15.
2. Ali S, Stone MA, Peters JL, et al. The prevalence of co-morbid depression in adults with type 2 diabetes: a systematic review and meta-analysis. Diabet Med. 2006;23:1165-1173.
3. Egede LE, Nietert PJ, Zheng D. Depression and all-cause and coronary heart disease mortality among adults with and without diabetes. Diabetes Care. 2005;28:1339-1345.
4. Egede LE, Ellis C. The effects of depression on diabetes knowledge, diabetes self-management, and perceived control in indigent patients with type 2 diabetes. Diabetes Technol Ther. 2008;10:213-219.
5. Katon WJ, Russo JE, Von Korff M, et al. Long-term effects on medical costs of improving depression outcomes in patients with depression and diabetes. Diabetes Care. 2008;31:1155-1159.
6. deGroot M, Anderson R, Freedland KE, et al. Association of depression and diabetes complications: A meta-analysis. Psychosom Med. 2001;63: 619-630.
7. Lustmann PJ, Clouse RE, Nix BD, et al. Sertraline for prevention of depression recurrence in diabetes mellitus. Arch Gen Psychiatry. 2006; 63:521-529.
8. Gülseren L, Gülseren S, Hekimsoy Z, et al. Comparison of fluoxetine and paroxetine in type 2 diabetes mellitus patients. Arch Med Res. 2005; 36:159-165.
9. Bogner HR, Morales KH, de Vries HF, Cappola AR. Integrated management of type 2 diabetes mellitus and depression treatment to improve medication adherence: a randomized controlled trial. Ann Fam Med. 2012;10:15-22.
10. Filipcic I, Margetic B, Simunovic I, Jakovljevic M. Depression treatment and its impact upon the quality of life in patients with diabetes type 2 - the Croatian study. Psychiatria Danubina. 2010;22:231-235.
11. Abrahamian H, Hofmann P, Prager R, Toplak H. Diabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group). Neuropsychiatr Dis Treat. 2009;5:261-266.
12. Osterreichische Diabetes Gesellschaft. Diabetes mellitus - guidelines for the practice. Revised and expanded 2007 edition. Wien Klin Wochenschr. 2009;121(Suppl 5):S1-S87. Article in German.
13. Whooley MA, Avins AL, Miranda J, et al. Case-finding instrument for depression. J Gen Intern Med. 1997;12:439-445.
14. Beck AT, Beamesderfer A. Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry. 1974;7:151-169.
15. Riedel M, Möller HJ, Obermeier M, et al. Response and remission criteria in major depression - a validation of current practice. J Psychiatr Res. 2010;44:1063-1068.
16. Rush WA, Whitebird RR, Rush MR, et al. Depression in patients with diabetes: does it impact clinical goals? J Am Board Fam Med. 2008;21: 392-397.
17. Gonzalez JS, Safren St A, Cagliero E, et al. Depression, self-care and medication adherence in type 2 diabetes. Diabetes Care. 2007;30: 2222-2227.
18. Lustmann PJ, Griffiti LS, Freedland KE, et al. Fluoxetine for depression in diabetes. Diabetes Care. 2000;23:618-623.
19. Amsterdam JD, Shults J, Rutherford N, et al. Safety and efficacy of s-citalopram in patients with comorbid major depression and diabetes mellitus. Neuropsychobiology. 2007;54:208-214.
20. Lustmann PJ, Williams MW, Sayur GS, et al. Factors influencing glycemic control in type 2 diabetes during acute- and maintenance-phase treatment of major depressive disorder with bupropion. Diabetes Care. 2007;30:459-466.
21. Montgomery SA. Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants. CNS Spectr. 2008;13:7(Suppl 11):27-33.
22. Lopez-Ibor J, Guelfi JD, Pletan Y, et al. Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychophamacol. 1996;11(Suppl 4):41-46.
23. Clerc G; Milnacipran/Fluvoxamine Study Group. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine. Int Clin Psychopharmacol. 2001;16:145-151.
24. Sechter D, Vandel P, Weiller E, et al. A comparative study of milnacipran and paroxetine in outpatients with major depression. J Affect Disord. 2004;83:233-236.
25. Gonzalez JS, Peyrot M, McCarl LA, et al. Depression and diabetes treatment non-adherence: A meta-analysis. Diabetes Care. 2008;31: 2398-2403.
26. Markowitz S, Gonzalez JS, Wilkinson JL, Safren SA. A review of treating depression in diabetes: emerging findings. Psychosomatics. 2011;52:1-18.